Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.
Eva Ciruelos, Aleix Prat(Hospital Clínic de Barcelona), Blanca Cantos Sanchez de Ibarguren(Hospital Universitario Puerta de Hierro Majadahonda), Sònia Pernas, Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Juan de la Haba-Rodríguez(Instituto Maimónides de Investigación Biomédica de Córdoba), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Javier Cortés(Villa Maria Hospital), Lorea Villanueva, Mafalda Oliveira(Vall d'Hebron Institut de Recerca), José Ponce(GEICAM – Spanish Breast Cancer Group), Eduardo Martínez de Dueñas(Consorcio Hospitalario Provincial de Castellón), Santiago Escrivá-de-Romaní(Unknown), Mireia Melé(Hospital Universitari Sant Joan de Reus), Patricia Villagrasa, Álvaro Montaño(Hospital Universitario Virgen del Rocío), Antonia Perelló, Ana López González(GEICAM – Spanish Breast Cancer Group), Xavier González(Breast Cancer Research Foundation)
Cited by 8
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k